Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar 17;106(11):4355-9.
doi: 10.1073/pnas.0812183106. Epub 2009 Mar 2.

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis

Affiliations

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis

Danielle Burger et al. Proc Natl Acad Sci U S A. .

Abstract

Mechanisms of action as well as cellular targets of glatiramer acetate (GA) in multiple sclerosis (MS) are still not entirely understood. IL-1beta is present in CNS-infiltrating macrophages and microglial cells and is an important mediator of inflammation in experimental autoimmune encephalitis (EAE), the MS animal model. A natural inhibitor of IL-1beta, the secreted form of IL-1 receptor antagonist (sIL-1Ra) improves EAE disease course. In this study we examined the effects of GA on the IL-1 system. In vivo, GA treatment enhanced sIL-1Ra blood levels in both EAE mice and patients with MS, whereas IL-1beta levels remained undetectable. In vitro, GA per se induced the transcription and production of sIL-1Ra in isolated human monocytes. Furthermore, in T cell contact-activated monocytes, a mechanism relevant to chronic inflammation, GA strongly diminished the expression of IL-1beta and enhanced that of sIL-1Ra. This contrasts with the effect of GA in monocytes activated upon acute inflammatory conditions. Indeed, in LPS-activated monocytes, IL-1beta and sIL-1Ra production were increased in the presence of GA. These results demonstrate that, in chronic inflammatory conditions, GA enhances circulating sIL-1Ra levels and directly affects monocytes by triggering a bias toward a less inflammatory profile, increasing sIL-1Ra while diminishing IL-1beta production. This study sheds light on a mechanism that is likely to participate in the therapeutic effects of GA in MS.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
sIL-1Ra levels are elevated in sera of EAE mice treated with GA. (A) GA ameliorates EAE. C57BL/6 mice were injected s.c. daily with GA (150 μg) or vehicle (PBS solution) 7 d before immunization with 10 μg myelin oligodendrocyte glycoprotein 35–55 peptide (dpi, day post-immunization). (B) EAE mice treated (GA) or not (vehicle) were killed at disease peak and their serum analyzed for IL-1β and sIL-1Ra content. IL-1β was not detected (not shown).
Fig. 2.
Fig. 2.
sIL-1Ra levels are elevated in sera of patients with MS treated with GA. The levels of sIL-1Ra and IL-1β were measured in sera of patients with RRMS treated with GA or not treated, and age-matched healthy controls, as described in Table 1. IL-1β was under the detection limit (15 pg/mL) in all individuals. There was no significant difference between healthy controls and untreated patients with RRMS. Results are presented as a box plot (GraphPad Prism 4).
Fig. 3.
Fig. 3.
GA differentially regulates IL-1β and sIL-1Ra production in human monocytes. (A) Monocytes (5 × 104 cells/200 μL/well; 96-well plates) were activated with the indicated dose of GA. After 48 h, supernatants were harvested and the production of IL-1β (open circles) and sIL-1Ra (filled circles) were measured in triplicate wells and represented as mean ± SD. Results are representative of 3 different experiments. (B) Monocytes (5 × 104 cells/200 μL/well; 96-well plates) were preincubated for 1 h with or without 25 μg/mL GA and then cultured for 48 h in the presence or absence of CEsHUT (1 μg/mL) or LPS (100 ng/mL). sIL-1Ra was measured in culture supernatants (mean ± SD, n = 3 different experiments). (C) Monocytes (5 × 104 cells/200 μL/well; 96-well plates) were preincubated for 1 h with or without 25 μg/mL GA and then cultured for 48 h in the presence or absence of CEsHUT (6 μg/mL) or LPS (100 ng/mL). IL-1β was measured in culture supernatants (mean ± SD, n = 3 different experiments, i.e., monocytes prepared from 3 different blood donors).
Fig. 4.
Fig. 4.
GA affects sIL-1Ra and IL-1β mRNA in both CEsHUT-activated and resting monocytes. (A) Monocytes (2 × 106 cells/well/3 mL) were preincubated for 1 h with the indicated dose of GA and then cultured for 3 h in the presence of CEsHUT (6 μg/mL). Total mRNA was isolated and analyzed by duplex real-time quantitative PCR (see Materials and Methods) for the presence of IL-1β (open circles) and sIL-1Ra (filled circles) transcripts. Results are presented as percentage of mRNA expression level, 100% being transcript expression measured after 3 h of monocyte activation by CEsHUT in the absence of GA; mean ± SD of 3 different experiments. (B) Monocytes (2 × 106 cells/well/3 mL) were activated for 18 h with the indicated dose of GA. Total mRNA was isolated and analyzed by duplex real-time quantitative PCR (see Materials and Methods) for the presence of IL-1β (open circles) and sIL-1Ra (filled circles) transcripts. Results are presented as percentage of mRNA expression level, 100% being the transcript level at 50 μg/mL GA; mean ± SD of 3 different experiments, i.e., monocytes prepared from 3 different blood donors.

Similar articles

Cited by

References

    1. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2001;2:1149–1165. - PubMed
    1. Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–1276. - PubMed
    1. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001;56:702–708. - PubMed
    1. Weber MS, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127:1370–1378. - PubMed
    1. Kim HJ, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172:7144–7153. - PubMed

Publication types

MeSH terms